Utilización de ansiolíticos e hipnóticos en España (1995-2002)

Pozo, Javier García del; Iglesias, Francisco J. de Abajo; García-Pando, Alfonso Carvajal; Corominas, Dolores Montero; Sanz, Mariano Madurga; Pozo, Victorina García del

doi:10.1590/s1135-57272004000300007

Cited by 24 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding the prevalence of use of anxiolytics and hypnotics, two different patterns were observed. Anxiolytics were more frequently prescribed than hypnotics in three databases (BIFAP, Bavarian and Mondriaan‐AHC), which is in line with previous published results, whereas hypnotics were more frequently used in three other databases (CPRD, THIN and DKMA), as also described previously . These differences may have several explanations.…”

Section: Discussionsupporting

confidence: 90%

“…This is probably the consequence of the initiatives taken by official bodies and the scientific community, in order to rationalize the use of BZDs. The Spanish BIFAP is the only database where a steady and relevant increase was observed over the study period, which is consistent with results from other studies . Population databases may be an important tool to assess trends and evaluate the effectiveness of prescribing recommendations.…”

Section: Discussionsupporting

confidence: 87%

“…Only five studies published in the last 15 years were identified, with a cross‐national comparison . Other published studies are country or region specific . Most of these studies investigated the broader group of psychotropic medication, including other drugs different from BZDs, which yielded different exposure definitions .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross‐national descriptive study from the PROTECT‐EU Project

Huerta

Abbing‐Karahagopian

Requena

et al. 2015

Pharmacoepidemiology and Drug

104

View full text Add to dashboard Cite

Purpose Studies on drug utilization usually do not allow direct cross-national comparisons because of differences in the respective applied methods. This study aimed to compare time trends in BZDs prescribing by applying a common protocol and analyses plan in seven European electronic healthcare databases. Methods Crude and standardized prevalence rates of drug prescribing from 2001-2009 were calculated in databases from Spain, United Kingdon (UK), The Netherlands, Germany and Denmark. Prevalence was stratified by age, sex, BZD type [(using ATC codes), i.e. BZD-anxiolytics BZD-hypnotics, BZD-related drugs and clomethiazole], indication and number of prescription. Results Crude prevalence rates of BZDs prescribing ranged from 570 to 1700 per 10 000 person-years over the study period. Standardization by age and sex did not substantially change the differences. Standardized prevalence rates increased in the Spanish (+13%) and UK databases (+2% and +8%) over the study period, while they decreased in the Dutch databases (À4% and À22%), the German (À12%) and Danish (À26%) database. Prevalence of anxiolytics outweighed that of hypnotics in the Spanish, Dutch and Bavarian databases, but the reverse was shown in the UK and Danish databases. Prevalence rates consistently increased with age and were two-fold higher in women than in men in all databases. A median of 18% of users received 10 or more prescriptions in 2008. Conclusion Although similar methods were applied, the prevalence of BZD prescribing varied considerably across different populations. Clinical factors related to BZDs and characteristics of the databases may explain these differences.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross‐national descriptive study from the PROTECT‐EU Project

Huerta

Abbing‐Karahagopian

Requena

et al. 2015

Pharmacoepidemiology and Drug

104

View full text Add to dashboard Cite

show abstract

“…En nuestro estudio, el tóxico implicado en el 47,6% de los casos corresponde al etanol, ya sea analizado de manera aislada o en combinación con otros fármacos, en los últimos 20 años siempre se ha considerado el tóxico implicado en la mayoría de las IA (de las Cuevas, Sanz, de la Fuente, Cabrera y Mateos, 1999;García del Pozo et al, 2004). La segunda sustancia son las benzodiacepinas, fármacos que necesitan receta médica pero que son muy accesibles a la población y están presentes de forma aislada en el 33,7% de las IA (Bugarin, Galego, Gude, García y Galban, 2000;Carpintero Escudero et al, 2000;Fernández, Sertral, Bermejo y Tabernero, 2005).…”

Section: Discussionunclassified

Epidemiología de las intoxicaciones agudas por sustancias de abuso en Urgencias. Estudio descriptivo en el área IV de Asturias

et al. 2021

View full text Add to dashboard Cite

La incidencia de las intoxicaciones agudas ha aumentado en los últimos años, y actualmente constituye aproximadamente el 2% de las atenciones sanitarias llevadas a cabo por los Servicios de Urgencias. El objetivo de este estudio es describir la frecuencia y características de las intoxicaciones atendidas en el Hospital Universitario Central de Asturias durante el año 2015 desde la perspectiva bioquímica-analítica, epidemiológica y médico-legal. Se realizó un estudio retrospectivo y un análisis descriptivo de las variables clínicas y sociodemográficas incluidas en el protocolo de intoxicación aguda a nivel nacional. Este hospital atendió 2478 casos de intoxicaciones agudas representando el 2,3% de las urgencias atendidas y que corresponde a una incidencia de 764 casos/100000 habitantes/año con un rango de edad de menores de 1 año a mayores de 80 años. La edad media de los pacientes atendidos fue de 43,6 (DE = 16,6) años. El 59,4% de los pacientes eran varones con una edad media de 44 (DE = 16,8) años, las mujeres representaban el 43,1% y su edad media era de 42,8 (DE = 16,5) años. El 47,2% de estas intoxicaciones ocurren durante el fin de semana y el 37,4% se dan entre junio y septiembre. La intencionalidad más frecuente es la intoxicación aguda voluntaria correspondiente al 83,2% de los casos. Cabe destacar que el 16,8% de los casos están referenciados en su historia clínica como intentos de suicidio. Los tóxicos más empleados son el etanol y las benzodiacepinas. Estas intoxicaciones son resueltas en el Servicio de Urgencias sin requerir ingreso hospitalario y poseen una tasa de mortalidad muy baja.

show abstract

“…BZDs are widely prescribed throughout Spain and in most Western countries [1-3]. The last Spanish National Health Survey [4] showed that 14.3% of subjects had used BZD in the previous 2 weeks, including 29.9% of women over 65 years of age.…”

Section: Introductionmentioning

confidence: 99%

Comparative efficacy of two primary care interventions to assist withdrawal from long term benzodiazepine use: A protocol for a clustered, randomized clinical trial

et al. 2011

View full text Add to dashboard Cite

BackgroundAlthough benzodiazepines are effective, long-term use is not recommended because of potential adverse effects; the risks of tolerance and dependence; and an increased risk of hip fractures, motor vehicle accidents, and memory impairment. The estimated prevalence of long-term benzodiazepine use in the general population is about 2,2 to 2,6%, is higher in women and increases steadily with age. Interventions performed by General Practitioners may help patients to discontinue long-term benzodiazepine use. We have designed a trial to evaluate the effectiveness and safety of two brief general practitioner-provided interventions, based on gradual dose reduction, and will compare the effectiveness of these interventions with that of routine clinical practice.Methods/DesignIn a three-arm cluster randomized controlled trial, general practitioners will be randomly allocated to: a) a group in which the first patient visit will feature a structured interview, followed by visits every 2-3 weeks to the end of dose reduction; b) a group in which the first patient visit will feature a structured interview plus delivery of written instructions to self-reduce benzodiazepine dose, or c) routine care. Using a computerized pharmaceutical prescription database, 495 patients, aged 18-80 years, taking benzodiazepine for at least 6 months, will be recruited in primary care health districts of three regions of Spain (the Balearic Islands, Catalonia, and Valencia). The primary outcome will be benzodiazepine use at 12 months. The secondary outcomes will include measurements of anxiety and depression symptoms, benzodiazepine dependence, quality of sleep, and alcohol consumption.DiscussionAlthough some interventions have been shown to be effective in reducing benzodiazepine consumption by long-term users, the clinical relevance of such interventions is limited by their complexity. This randomized trial will compare the effectiveness and safety of two complex stepped care interventions with that of routine care in a study with sufficient statistical power to detect clinically relevant differences.Trial RegistrationCurrent Controlled Trials: ISRCTN13024375

show abstract

Utilización de ansiolíticos e hipnóticos en España (1995-2002)

Cited by 24 publications

References 17 publications

Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross‐national descriptive study from the PROTECT‐EU Project

Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross‐national descriptive study from the PROTECT‐EU Project

Epidemiología de las intoxicaciones agudas por sustancias de abuso en Urgencias. Estudio descriptivo en el área IV de Asturias

Comparative efficacy of two primary care interventions to assist withdrawal from long term benzodiazepine use: A protocol for a clustered, randomized clinical trial

Contact Info

Product

Resources

About